INBEC is a fixed-dose combination of:
Abacavir – a nucleoside reverse transcriptase inhibitor (NRTI)
Lamivudine – NRTI
Dolutegravir – integrase strand transfer inhibitor (INSTI)
Mechanism of action:
Inhibits essential viral enzymes
Reduces viral load
Increases CD4 cell count
Recommended for:
Adults and adolescents with HIV-1
First-line ART treatment
Patients with resistance to other regimens
Individuals with good adherence
Treatment of HIV-1 infection in adults and adolescents aged 12 and above
Maintenance of viral suppression
Part of antiretroviral therapy (ART) regimens
INBEC should be taken orally once daily, with or without food. Dosage and treatment duration are determined by the prescribing physician based on viral load, treatment history, and clinical status.
Hypersensitivity to any component
Positive HLA-B*5701 allele (risk of Abacavir hypersensitivity)
Severe hepatic impairment
Pregnancy (only if deemed necessary by a physician)
Headache, insomnia
Nausea, diarrhoea
Elevated liver enzymes
Hypersensitivity reactions
Fat redistribution
Dyslipidaemia
Anxiety or depression
